Table 1.

Baseline characteristics

	DMAb (n = 427)a	BP (n = 78)b	p value
Age	69.2 ± 10.3	67.9 ± 8.4	NS
Weight (kg)	57.1 ± 10.8	56.3 ± 12.7	NS
BMI (kg/m2)	26.2 ± 8.6	28.7 ± 18.4	NS
% YAM	54.1 ± 13.0	56.3 ± 13.8	NS
NTX (nmolBCE/mmolCr)	64.7 ± 25.0	66.2 ± 31.1	NS

Data are presented as mean ± standard error

BMI body mass index, BP bisphosphonate-treated group, DMAb denosumab-treated group, nmolBCE/mmolCr nmol Bone Collagen Equivalents/nmol creatinine, NS not statistically significant, PO patients with postmenopausal osteoporosis, RA osteoporosis patients with rheumatoid arthritis, RA + GC osteoporosis patients with rheumatoid arthritis taking glucocorticoids, NTX type I collagen cross-linked N-telopeptide, YAM young adult mean

^aPO (n = 205), RA (n = 156), RA + GC (n = 66)

^bPO (n = 44), RA (n = 34)